Local SGc is most commonly managed with local resection and/or radiation therapy. Systemic therapy for metastatic disease is not well described, and may include conventional chemotherapy, targeted therapies (anti-androgen, EGFR inhibitors, and retinoid receptor ligands), and immunotherapy. Surgical resection Wide local excision and Mohs micrographic surgery (MMS) are the mainstay of treatment for both periocular and extraocular. Unlike wide local excision, MMS allows for precise and accurate removal of the tumor and complete assessment of margins. Furthermore, MMS is associated with significantly lower local and distant recurrence rates in both periocular and extraocular SGc, when compared to wide local excision. MMS also limits morbidity and is useful in cosmetically sensitive areas such as the face. According to the MMS appropriate use criteria (AUC), MMC may be considered for SGc in any location, unlike basal cell or squamous cell carcinoma, given the high recurrence rates and potentially aggressive nature of SGc. Radiation therapy Radiotherapy is associated with higher recurrence rates and mortality when compared to surgical excision. It is not recommended as a primary therapy and is only for patients who cannot undergo or refuse surgical excision. Potential adverse effects from radiation include keratitis, conjunctivitis, dry eyes, keratitis and loss of vision. Chemotherapy There is a limited amount of information on the effectiveness of chemotherapy for SGc, and it is not indicated for local disease. Few studies have shown topical adjuvant chemotherapy to be effective in treating SGc. Neoadjuvant chemotherapy may be used in advanced tumors to allow for local resection and to avoid highly morbid procedures, such as exenteration. Adjuvant Radiation Therapy Postsurgical adjuvant radiation therapy has been used in locally advanced primary tumors and those with positive margins or perineural invasion. Data on the role of adjuvant radiation therapy in the treatment of SGc is<unk> arce, however, and recurrence following adjuvant radiation therapy has been reported.
Sebaceous carcinoma
Medulloepithelioma
Lymphoepithelioma
Bartholin gland carcinoma
Basal-cell carcinoma
Trichoepithelioma
Pyogenic granuloma
Angiokeratoma